Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2690 - Phase II clinical trial with axitinib as maintenance therapy in patients (p) with metastatic colorectal carcinoma (CRC)


08 Oct 2016


Poster Display


Cristina Gravalos


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


C. Gravalos1, A. Carrato2, M. Tobeña3, E. Grande Pulido2, G. Soler4, J. Vieitez5, L. Robles6, M. Valladares-Ayerbes7, E. Polo8, M.L. Limon9, M.J. Safont10, C. Lopez11, P. García Alfonso12, E. Aranda13

Author affiliations

  • 1 Medical Oncology, University Hospital 12 De Octubre, 28041 - Madrid/ES
  • 2 Medical Oncology, Hospital Universitario Ramon y Cajal, 28031 - Madrid/ES
  • 3 Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08026 - Barcelona/ES
  • 4 Medical Oncology, ICO Hospital Duran i Reynals, Hospitalet/ES
  • 5 Medical Oncologist, Hospital Universitario Central de Asturias, Oviedo/ES
  • 6 Medical Oncology, University Hospital 12 De Octubre, 28031 - Madrid/ES
  • 7 Medical Oncology, Hospital Universitario a Coruna - a Corunac, A Coruna/ES
  • 8 Medical Oncology, Hospital Miguel Servet, Zaragoza/ES
  • 9 Medical Oncology, Hospital Universitario Virgen del Rocio, Sevilla/ES
  • 10 Medical Oncology, Hospital General Universitario Valencia, Valencia/ES
  • 11 Medical Oncology, Hospital Universitario Marques de Valdecilla, Santander/ES
  • 12 Medical Oncology, Hospital General Universitario Gregorio Marañon, Madrid/ES
  • 13 Medical Oncology, Reina Sofía Hospital, University of Córdoba, Maimonides Institute of Biomedical Research (IMIBIC). Spanish Cancer Network (RTICC), Instituto de Salud Carlos III,, 14004 - Cordoba/ES


Abstract 2690


The prognosis of advanced CRC p has improved during last years. Nevertheless, treatment options in this situation are still limited. Maintenance therapy with bevacizumab has been stablished as standard of care after bevacizumab plus fluropyrimidine based chemotherapy. Axitinib is a novel drug targeting VEGFR1, 2 and 3, with contradictory results in CRC


In this phase 2 randomized double blinded trial, axitinib (5 mg/bid) was compared to placebo in metastatic CRC p who had not progressed after 6-8 months of first line treatment with chemotherapy with or without bevacizumab or cetuximab. The primary objective was progression-free survival (PFS) at 6 months. Secondary objectives included overall survival (OS), response rate (RR) and safety


A total of 49 p were included: 25 cohort A (axitinib) and 24 cohort B (placebo). Baseline characteristics were well balanced. Mean age was 66 years (Standard Deviation (SD) ±10.35); 33 (67%) were men; ECOG Performance status was 0 for 19 p and 1 for 30 p. PFS at 6 months was 40% (Confidence Interval (CI) 95% 21.28, 58.12) for cohort A and 8.33% (CI95% 1.44, 23.30) for cohort B; p-value p = 0.01. Median PFS was 4.96 months in cohort A and 3.16 months for cohort B; Hazard Ratio (HR) 0.46 (0.2515, 0.8565), p = 0.0116. Median OS was 27.61 months in cohort A (CI: 14.96; 38.94), and 19.99 months (CI: 12.08; 27.35) in cohort B, p = 0.3279. The study was prematurely closed due to lack of accrual; however p-value of the log-rank contrast was significant. Regarding safety, grade 3-4 treatment related toxicities were experienced by 7 p (28%) in cohort A and 1 p (4%) in cohort B. The most frequent grade 3-4 treatment related toxicities were hypertension in 6% and 2%; diarrhea in 4% and 0%, asthenia in 2% and 0% in cohort A and B, respectively. There were no toxic deaths


Maintenance treatment with axitinib in advanced CRC with no progression after first line chemotherapy is associated with a significantly increased PFS when compared to placebo. Axitinib was well tolerated with few SAEs. The initially estimated sample size was not reached, but the study drug should be further studied in this setting since promising efficacy data were met

Clinical trial identification

EudraCT: 2011-002384-16

Legal entity responsible for the study

Spanish Cooperative Group for the Digestive Tumour Therapy


Pfizer, New York, NY, USA


A. Carrato: Consultant or advisore role: Amgen, Merck, Roche. M. Valladares-Ayerbes: Consultant or advisory role: Amgen, Bayer. C. Lopez: Consultant or advisory role Amgen, Pfizer, Celgene, Sanofi, Roche, Novartis, Ipsen. P. García Alfonso: Advisory role: Roche, Merck, Amgen, Sanofi, Lilly y Bayer. E. Aranda: advisory role from Amgen, Bayer, Celgene, Merk, Roche and Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings